02 June 2016

Bayer Media Discussion: Men’s Intimate Issues (Seputar Masalah Intim Lelaki / SMILe) - Hypogonadism Caused Risk of Death

  • Reversible effect between hypogonadism and metabolic syndrome.
  • Hypogonadism is a risk factor for metabolic syndrome as a silent killer.
  • Testosterone therapy is required for patients with hypogonadism and metabolic 
syndrome. 


PT Bayer Indonesia as Life Science’s company is committed to inform, educate, and communicate health-related issues to public. Therefore, Bayer held a media discussion: Men’s Intimate Issues (Seputar Masalah Intim Lelaki / SMILe) with topic – Hypogonadism Caused Risk of Death. In this media discussion is revelead the evidence base related the reversible effect between hypogonadism and metabolic syndrome as a silent killer.

 

What is in you mind when you hear the word 'testosterone', which is also known as 'male hormone'? Many people, even the medical practisioners certainly associate it with sex hormones and muscle strength. Indeed, testosterone is essential for organ development and maintains sexual function or male reproductive and it plays significant role for men’s cycle life. Actually, the last few years, many studies shown that the decrease in testosterone levels causes a decrease in bone density and an increased incidence of bone fractures, decreased red blood cells, decreased muscle mass and increased fat, depression and mood disorders. The most serious medical condition is the increased risk of metabolic syndrome and coronary heart disease that eventually leads to death.

 

According to the National Health Institute, USA, metabolic syndrome is the name for a group of risk factors that raises the risk for heart disease and other health problems, such as diabetes and stroke. Based on medical studies, obviously, having any one of these risk factors isn't good. But when they're combined, they set the stage for serious problems. These risk factors double the risk of blood vessel and heart disease, which can lead to heart attacks and strokes. They increase risk of diabetes by five times, if the person is suffering from metabolic syndrome after 5-10 year1. Dr. Johannes Soedjono, Kes.,Sp.And said that the risk factors for metabolic syndrome tend to occur together. "If a man suffering from metabolic syndrome, then the posibilities to suffers hypogonadism is triple and the prevelence rate of deaths increased by about one and a half times. In addition, the decreasing of testosterone level in man body is related also with age. This decline is about 2-3% per year. At the age of 40 years, the testosterone levels to approximately 65-70% and at the age of 60 years and above about 45-50% of the age of 25 years old", said Dr. Johanes.

 

Most of elderly men ignore the symptoms such as decreased libido, erectile dysfunction, fatigue, easy sweating, increase waist and sleepy after eating. They thought that these condition is common caused related with the age. Actually, these symptoms are the indication that a man has suffers hypogonadism or testosterone deficiency syndrome (TDS). The low level of testosterone according to the European Society of Sexual Medicine (ESSM) is 300 ng / dl.

 

The reversible effect between hypogonadism, metabolic syndrome and heart disease and blood vessels has been proven both experimentally and clinically. Therefore, to reduce the risk of death from heart disease for men with hypogonadism, either accompanied or who have metabolic syndrome, testosterone hormone replacement therapy is essential to cut the chain of these reversible effect. A men who suffers hypogonadism, will also suffers blood vessel and heart disease3.

 

Study shown that testosterone therapy can improve each component of metabolic syndrome, reduced fat mass, improve muscle mass, lowers blood sugar levels, improve insulin sensitivity, improves lipid so that the LDL cholesterol and trigleserid can decrease and HDL increased, can reduce blood pressure both systolic and diastolik4, " said Dr. Johannes.

 

Same as other diseases, a healthy lifestyle is required if some one wants to remain healthy until elderly age.

 

References:

  1. National Health Statistics Reports No.13, May 5, 2009: Prevalence of Metabolic Syndrome Among Adults 20 Years of Age and Over, by Sex, Age, Race and Ethnicity, and Body Mass Index: United States, 2003– 2006, by R. Bethene Ervin, Ph.D., R.D., Division of Health and Nutrition Examination Surveys.
  2. www.nhlbi.nih.gov/health/health-topics/topics/ms
  3. Bodie J et al. J Urol 2003; 169:2262–2264.
  4. Diabetes UK, personal communication. 27/02/09.

 

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com or www.bayer.co.id.

 

Media Contact:

Anton Susanto

Head of Communications
PT Bayer Indonesia

Phone: +62-21-30491506

E-mail: anton.susanto@bayer.com

 

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.co.id The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

 

 

L.ID.COM.GM.05.2016.0999